Mike Biega
Vice President of Investor Relations and Communications
Replay available
Harrow, Inc. (NASDAQ: HROW) Q3 2025 earnings conference call, held 2025-11-11. Replay captured from the company's public earnings webcast.

Vice President of Investor Relations and Communications
Chief Executive Officer
President and Chief Financial Officer
Head of Commercial
Analyst, Ladenburg
Analyst, Craig‐Hallam
Analyst, Cantor Fitzgerald
Analyst, B. Riley Securities
Analyst, Lake Street Capital Markets
Analyst, BTIG
Analyst, H.C. Wainwright
Good day, and welcome to the HARO Third Quarter 2025 Earnings Conference Call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question and answer session. Instructions will be given at that time. As a reminder, this call may be recorded. I would like to turn the call over to Mike Biega, Vice President of Investor Relations and Communications. Please go ahead. Thank you, Operator. Good morning, and welcome to HARO's third quarter 2025 earnings conference call. My name is Mike Biega, Vice President of Investor Relations and Communications, and I'm excited to be introducing today's call. Similar to our last quarterly call, we will be presenting slides during the webcast today. If you have registered and joined through the live conference call link, I would highly recommend that you also join through the webcast. You can find the link in the investor section of our website at www.harrow.com or in our earnings press release that was issued yesterday. The company's remarks may include forward-looking statements within the meaning of federal securities laws. Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond HARO's control, including risks and uncertainties described from time to time in its SEC filings, such as the risks and uncertainties related to the company's ability to make commercially available FDA-approved products and compounded formulations and technology and FDA approval of certain drug candidates in a timely manner or at all. For a list and description of those risks and uncertainties, please see the risk factors section of the company's most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q filed with the Securities and Exc...